BIOMARIN PHARMACEUTICAL INC
StreetZero Signal 57
About BIOMARIN PHARMACEUTICAL INC
BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing and commercializing therapies for rare genetic diseases. Founded in 1997 by Christopher Starr and Grant W. Denison Jr., it went public in 1999 and trades on NASDAQ under BMRN. The company is headquartered in San Rafael, CA, operates a B2B model, and maintains social profiles on Facebook, Twitter, and Instagram.
LATEST FUNDINGRule 144
$303K
Announced 2026-11-18
TOTAL RAISED1.82B USD
IN THE NEWS
- ๐ BioMarin Pharmaceutical Inc.
- ๐ BioMarin Pharmaceutical - 2026 Company Profile, Funding, Competitors & Financials - Tracxn
- ๐ BioMarin Pharmaceutical - 2026 Company Profile, Funding, Competitors & Financials - Tracxn
- ๐ BioMarin Pharmaceutical - Wikipedia
- ๐ BioMarin Reports Second Quarter 2026 Financial and Operating Results
EMPLOYEESโ
FOUNDED1997
HQSan Rafael, CA, United States
Industry
Public Equity (NASDAQ)
Tags
BiotechnologyPublic CompanyRare DiseasesB2B
Key highlights
- BioMarin was founded in 1997 with seed investment from Glyko Biomedical and went public in 1999.
- Total funding reached 1.82B USD with last reported round as post-IPO debt in 2026.
- Company maintains 239,250 LinkedIn followers and focuses on rare-disease drug development.
- Acquired Glyko Biomedical in 2002 and has faced criticism over drug pricing practices.
Ask StreetZero about BIOMARIN PHARMACEUTICAL INC
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account